MA53020A - Protéine de fusion du fviii améliorée et utilisation associée - Google Patents

Protéine de fusion du fviii améliorée et utilisation associée

Info

Publication number
MA53020A
MA53020A MA053020A MA53020A MA53020A MA 53020 A MA53020 A MA 53020A MA 053020 A MA053020 A MA 053020A MA 53020 A MA53020 A MA 53020A MA 53020 A MA53020 A MA 53020A
Authority
MA
Morocco
Prior art keywords
fusion protein
associated use
fviii fusion
enhanced fviii
enhanced
Prior art date
Application number
MA053020A
Other languages
English (en)
French (fr)
Inventor
Xian Chen
Jie Gao
Haitao Hu
Lingli Huang
Xiang Li
Bin Liu
Zijia Ren
Hongsheng Su
Qilei Wang
Shuang Wang
Shuya Wang
Wenwen Wang
Xiaoshan Wang
Yali Wang
Chunfeng Xiao
Lili Zhang
Luyan Zhu
Original Assignee
Zhengzhou Gensciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhengzhou Gensciences Inc filed Critical Zhengzhou Gensciences Inc
Publication of MA53020A publication Critical patent/MA53020A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA053020A 2018-05-18 2019-05-16 Protéine de fusion du fviii améliorée et utilisation associée MA53020A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810481941 2018-05-18

Publications (1)

Publication Number Publication Date
MA53020A true MA53020A (fr) 2021-05-05

Family

ID=68539524

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053020A MA53020A (fr) 2018-05-18 2019-05-16 Protéine de fusion du fviii améliorée et utilisation associée

Country Status (9)

Country Link
US (1) US12440572B2 (https=)
EP (1) EP3816181A4 (https=)
JP (2) JP2021530437A (https=)
KR (1) KR102575788B1 (https=)
CN (2) CN117467019A (https=)
BR (1) BR112020023168A2 (https=)
MA (1) MA53020A (https=)
MX (1) MX2020012103A (https=)
WO (1) WO2019219049A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025521136A (ja) * 2022-05-25 2025-07-08 チアンスー ジェンサイエンス インコーポレイテッド 半減期が延長されたｆｖｉｉｉ融合タンパク質コンジュゲート及びその応用
CN116284411B (zh) * 2023-02-03 2024-02-13 北京基科晟斯医药科技有限公司 抗培重组人凝血因子VIII-Fc融合蛋白的抗体及其应用
CN116036244B (zh) * 2023-02-24 2023-09-19 北京基科晟斯医药科技有限公司 培重组人凝血因子VIII-Fc融合蛋白用于治疗含抑制物的血友病A的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818679A (en) 1985-02-19 1989-04-04 The Trustees Of Columbia University In The City Of New York Method for recovering mutant cells
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
JP2001510053A (ja) 1997-07-18 2001-07-31 カイロン コーポレイション レンチウイルスベクター
KR101468345B1 (ko) 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
EP1891231A4 (en) 2005-05-25 2011-06-22 Novo Nordisk As GLYCOPEGYLATED FACTOR IX
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
WO2010083536A1 (en) 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety
CN105153313A (zh) * 2010-02-16 2015-12-16 诺沃—诺迪斯克有限公司 因子viii融合蛋白
US20130040888A1 (en) 2010-02-16 2013-02-14 Novo Nordisk A/S Factor VIII Molecules With Reduced VWF Binding
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
CN103917554B (zh) 2011-10-18 2017-03-08 杰特有限公司 用于改善重构后纯化的因子viii的稳定性的方法
CN103172745A (zh) 2011-12-21 2013-06-26 北京韩美药品有限公司 包含免疫球蛋白Fc片段的长效人内皮抑素
DK2804623T3 (da) * 2012-01-12 2019-11-11 Bioverativ Therapeutics Inc Kimære faktor viii-polypeptider og anvendelser deraf
EP3404105A1 (en) * 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
JP2015527350A (ja) 2012-08-13 2015-09-17 ノヴォ ノルディスク アー／エス 第ｖｉｉｉ因子の液体製剤
WO2014100913A1 (en) 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
CN103539860B (zh) 2013-11-01 2014-12-03 广州优联康医药科技有限公司 一种长效重组人促卵泡激素融合蛋白
JP6851381B6 (ja) 2016-01-07 2021-04-21 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 変異切断型フォンウィルブランド因子
CN109790529A (zh) * 2016-06-24 2019-05-21 财团法人牧岩生命科学研究所 包含FVIII和vWF因子的嵌合蛋白及其用途
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途

Also Published As

Publication number Publication date
JP7492780B2 (ja) 2024-05-30
KR20210005248A (ko) 2021-01-13
CN117467019A (zh) 2024-01-30
EP3816181A1 (en) 2021-05-05
US12440572B2 (en) 2025-10-14
EP3816181A4 (en) 2022-04-20
BR112020023168A2 (pt) 2021-02-09
JP2023093634A (ja) 2023-07-04
WO2019219049A1 (zh) 2019-11-21
MX2020012103A (es) 2021-01-29
CN113039200A (zh) 2021-06-25
JP2021530437A (ja) 2021-11-11
CN113039200B (zh) 2023-07-25
KR102575788B1 (ko) 2023-09-08
US20210361775A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
IL279897A (en) Fusosome compositions and uses thereof
EP3802612A4 (en) ANTI-B7-H3 ANTIBODIES AND USE THEREOF
EP3797124A4 (en) ANTI-PD-L1 ANTIBODIES AND USE THEREOF
EP3880814A4 (en) FUSION PROTEIN
EP3698337C0 (en) HAND WASHING SYSTEM AND METHOD
EP3442579A4 (en) ANTI-HUMAN-VISTA ANTIBODIES AND USE THEREOF
IL268780A (en) Pd-l1 variant immunomodulatory proteins and uses thereof
MA44993A (fr) Polypeptides de fusion cd40l-fc et procédés d'utilisation associés
HRP20251600T1 (hr) Sustav i postupci
EP3680331A4 (en) MODIFIED CAS9 PROTEIN AND USE OF IT
EP3820887A4 (en) Pd1-4-1bbl variant fusion protein and methods of use thereof
EP3523332A4 (en) ANTI-HUMAN 4-1 BB ANTIBODY AND ITS USE
EP3810172A4 (en) Heterodimeric proteins and uses thereof
EP3430058A4 (en) MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
IL254165B (en) Immunomodulatory fusion proteins and uses thereof
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
EP3960756A4 (en) FLAGELLIN FUSION PROTEIN AND USE THEREOF
EP3882277A4 (en) FUSION PROTEIN AND USE THEREOF
EP3722305A4 (en) HM-3 FUSION PROTEIN AND USES THEREOF
IL280631A (en) Novel crispr-associated protein and use thereof
IL283942A (en) Tubulysins and protein-tubulysin conjugates
IL281297A (en) Anti-npr1 antibodies and uses thereof
EP3672443A4 (en) SUITCASE AND SUITCASE SYSTEM
EP3399033A4 (en) PEPTIDE MARKING AND MARKED PROTEIN THEREOF
EP3950720A4 (en) Fusion protein and use thereof